Author

Bruce B. Bank

Observed names: B B Bank, B Bank, B. Bank, Bruce Bank

Observed institutions: City Of Hope National Medical Center, University of California, San Francisco, Medical College of Wisconsin, University of Chicago, NYU Langone Health, City of Hope, VA Central California Health Care System, Rutgers New Jersey Medical School, New York University

OpenAlex ID: A5007140474

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

2019 · Maria-Victoria Mateos, Hilary Blacklock, et al. · The Lancet Haematology · 258

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

2023 · Srdan Verstovsek, Aaron T Gerds, et al. · The Lancet · 202

A Comparison of Efficacy of Sargramostim (Yeast-Derived RhuGM-CSF) and Filgrastim (Bacteria-Derived RhuG-CSF) in the Therapeutic Setting of Chemotherapy-Induced Myelosuppression

1998 · Roy A. Beveridge, John A. Miller, et al. · Cancer Investigation · 66

Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes.

1989 · B B Bank, D Kanganis, et al. · PubMed · 54

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer

2016 · Randy F Sweis, Sachdev Thomas, et al. · Cureus · 37

Studies of chlorambucil—DNA adducts

1992 · Bruce B. Bank · Biochemical Pharmacology · 21

Lack of drug-induced DNA cross-links in chlorambucil-resistant Chinese hamster ovary cells.

1989 · B Z Jiang, B B Bank, et al. · PubMed · 18

DNA topoisomerase II as a potential factor in drug resistance of human malignancies.

1987 · M Potmesil, Y H Hsiang, et al. · PubMed · 17

Studies on drug resistance in chronic lymphocytic leukemia

1989 · Robert Silber, Milan Potmesil, et al. · Advances in Enzyme Regulation · 11

Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study

2024 · Kevin C Flanagan, Jon Earls, et al. · Journal for ImmunoTherapy of Cancer · 9

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma

2023 · Kevin C. Flanagan, Jon Earls, et al. · Journal of Cancer Research and Clinical Oncology · 8

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors

2026 · Daruka Mahadevan, Jay Parekh, et al. · Investigational New Drugs · 1

Multicenter validation of an assay to predict anti-PD-1 disease control in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma: The PREDAPT Study

2024 · Kevin C. Flanagan, Jon Earls, et al. · medRxiv · 1

P2.12-07 Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression

2023 · J. Treat, N. Abdulla, et al. · Journal of Thoracic Oncology · 1

Validation of a tissue-based predictive RNA test for immunotherapy benefit in NSCLC: the PREDAPT study

2026 · Kevin C. Flanagan, Jon Earls, et al. · npj Precision Oncology

A first-in-human phase 1a study of LP-184, a tumor site–activated novel alkylating agent, in patients with advanced solid tumors.

2026 · Daruka Mahadevan, Jay Parekh, et al. · Journal of Clinical Oncology

Works count: 16

Citation count: 704

H-index: 9

I10-index: 9